Exclusive Interview with ASBM Released Ahead of Upcoming Biosimilars Conference
Exclusive interview with expert speaker from ASBM
Exclusive interview with expert speaker from ASBM
Pharma needs clarity from the Supreme Court on whether the whole scope of a patent claim must be plausible at the time of the application.
China has become more accepting of Western medicines and sees the value of a strong patenting process, opening the door for more foreign trade and mutual benefits.
Extending patents is restricting patients’ access to the treatments they need.
IP management can protect pharma companies’ investments and future R&D.
Sheila Swaroop and Kaitlin Heinen examine the findings of a recent report.